| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 911 | 2019 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 872 | 2019 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 624* | 2019 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 595 | 2019 |
| Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma A Perrot, V Lauwers-Cances, J Corre, N Robillard, C Hulin, ML Chretien, ... Blood, The Journal of the American Society of Hematology 132 (23), 2456-2464, 2018 | 381 | 2018 |
| Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy … P Moreau, M Attal, D Caillot, M Macro, L Karlin, L Garderet, T Facon, ... Journal of clinical oncology 35 (25), 2911, 2017 | 295 | 2017 |
| Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma T Facon, MA Dimopoulos, A Dispenzieri, JV Catalano, A Belch, M Cavo, ... Blood, The Journal of the American Society of Hematology 131 (3), 301-310, 2018 | 280 | 2018 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 235 | 2022 |
| Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide … C Thieblemont, H Tilly, M Gomes da Silva, RO Casasnovas, C Fruchart, ... Journal of Clinical Oncology 35 (22), 2473-2481, 2017 | 200 | 2017 |
| Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised … T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... The Lancet Oncology 22 (11), 1582-1596, 2021 | 199 | 2021 |
| Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma A Perrot, V Lauwers-Cances, E Tournay, C Hulin, ML Chretien, B Royer, ... Journal of Clinical Oncology 37 (19), 1657, 2019 | 153 | 2019 |
| A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis M Roussel, G Merlini, S Chevret, B Arnulf, AM Stoppa, A Perrot, ... Blood, The Journal of the American Society of Hematology 135 (18), 1531-1540, 2020 | 127 | 2020 |
| Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial A Perrot, V Lauwers-Cances, T Cazaubiel, T Facon, D Caillot, ... Blood 136, 39, 2020 | 123 | 2020 |
| LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma MV Mateos, K Weisel, V De Stefano, H Goldschmidt, M Delforge, M Mohty, ... Leukemia 36 (5), 1371-1376, 2022 | 118 | 2022 |
| Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant … P Moreau, C Hulin, A Perrot, B Arnulf, K Belhadj, L Benboubker, MC Bene, ... The Lancet Oncology 22 (10), 1378-1390, 2021 | 117 | 2021 |
| Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma E Zamagni, C Nanni, L Dozza, T Carlier, C Bailly, P Tacchetti, A Versari, ... Journal of Clinical Oncology 39 (2), 116-125, 2021 | 101 | 2021 |
| Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities A Perrot, I Luquet, A Pigneux, F Mugneret, J Delaunay, JL Harousseau, ... Blood, The Journal of the American Society of Hematology 118 (3), 679-685, 2011 | 87 | 2011 |
| Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma … T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... Blood 132 (Supplement 1), LBA-2-LBA-2, 2018 | 83 | 2018 |
| Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow C Mazzotti, L Buisson, S Maheo, A Perrot, ML Chretien, X Leleu, C Hulin, ... Blood advances 2 (21), 2811-2813, 2018 | 83 | 2018 |
| Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma T Dejoie, J Corre, H Caillon, C Hulin, A Perrot, D Caillot, E Boyle, ... Blood, The Journal of the American Society of Hematology 128 (25), 2941-2948, 2016 | 83 | 2016 |
nizar bahlisAssociate Professor, University of CalgaryVerified email at ucalgary.ca
